Kurt Gielen, MedAce, Maastricht, The Netherlands, discusses issues researchers and academics may face when commercializing their therapies for clinical use. Researchers may not have the relevant experience in manufacturing products, and due to the novel nature of the treatments, regulatory authorities may have difficulties in assessing them based on existing guidelines. This interview took place at the 6th World Congress of the Tissue Engineering and Regenerative Medicine International Society (TERMIS 2021).